0001209191-19-053060.txt : 20191011 0001209191-19-053060.hdr.sgml : 20191011 20191011173944 ACCESSION NUMBER: 0001209191-19-053060 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191009 FILED AS OF DATE: 20191011 DATE AS OF CHANGE: 20191011 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAVIS STEPHEN CENTRAL INDEX KEY: 0001131146 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 191148719 MAIL ADDRESS: STREET 1: NEUROGEN CORP STREET 2: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-10-09 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001131146 DAVIS STEPHEN C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, STE. 300 SAN DIEGO CA 92130 1 1 0 0 CEO Common Stock 2019-10-09 4 M 0 29792 19.65 A 29792 D Common Stock 2019-10-09 4 S 0 29792 40.001 D 0 D Common Stock 2019-10-10 4 M 0 120208 19.65 A 120208 D Common Stock 2019-10-10 4 S 0 120208 40.189 D 0 D Stock Option (Right to Buy) 19.65 2019-10-09 4 M 0 29792 0.00 D 2026-03-14 Common Stock 29792 570208 D Stock Option (Right to Buy) 19.65 2019-10-10 4 M 0 120208 0.00 D 2026-03-14 Common Stock 120208 450000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 22, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the 600,000 shares subject to the stock option vested and became exercisable on March 15, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Austin D. Kim, Attorney-in-Fact 2019-10-11